Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709343 | 1.00 | SLC1A1 (0.54) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL16000772 | 0.87 | SLC1A1 (0.65) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL12476475 | 0.84 | SLC1A1 (0.57) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL26197467 | 0.82 | SLC1A1 (0.48) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL8839263 | 0.79 | SLC1A1 (0.73) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL20279723 | 0.79 | SLC1A1 (0.43) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL1709304 | 0.78 | CA1 (0.46) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL1709283 | 0.78 | CYP1A2 (0.64) | SLC1A1FOLH1CYP1A2 | |
| SCHEMBL1709339 | 0.78 | CYP1A2 (0.64) | SLC1A1FOLH1CYP1A2 | |
| SCHEMBL5941631 | 0.77 | SLC1A1 (0.61) | SLC1A1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | SLC1A1 4477/4885CA1 3499/4885CA2 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.